Marisa Juárez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Marisa Juárez has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Javier Krolewiecki
Affiliations Fundación Mundo Sano, Madrid, Spain, Instituto de Investigaciones de Enfermedades Tropicales (IIET), Universidad Nacional de Salta, Orán, Salta, Argentina
3 shared publications - María Cristina Almazán
Instituto de Investigaciones de Enfermedades Tropicales, Facultad Regional Orán, Universidad Nacional de Salta, Orán, Argentina
2 shared publications - Ruben Oscar Cimino
Instituto de Investigaciones de Enfermedades Tropicales (IIET), Facultad Regional Orán, Universidad Nacional de Salta, Salta A4400, Argentina
2 shared publications - Adriana Echazú
Affiliations Fundación Mundo Sano, Madrid, Spain, Instituto de Investigaciones de Enfermedades Tropicales (IIET), Universidad Nacional de Salta, Orán, Salta, Argentina
1 shared publication - Carlos Lanusse
Laboratorio de Farmacología, Centro de Investigación Veterinaria de Tandil (CIVETAN), CONICET, Facultad de Ciencias Veterinarias, UNCPBA, Campus Universitario, Tandil 7000, Argentina
1 shared publication - Fabian Schär
Swiss Tropical and Public Health Institute, Basel, Switzerland
1 shared publication
Latest Publications
- Open Access
- 8 December 2021
- Published by Wiley in European Journal of Inorganic Chemistry
- Vol. 2022 (1)
A Strongly Coupled Biruthenium Complex as Catalyst for the Water Oxidation Reaction
The catalytic activity towards water oxidation of a strongly coupled bimetallic ruthenium complex, trans‐[Ru(tpy)(bpy)(μ‐CN)Ru(py)4(OH2)]3+ (RuIIRuIIOH2), where tpy=2,2′:6′,2’’‐terpyridine, bpy=2,2′‐bipyridine and py=pyridine are presented. At pH 1 the first two oxidation reactions are centred at the aquo fragment and result in the RuIIRuIIIOH2 and RuIIRuIVO redox states as confirmed by its spectroscopy and DFT calculations. Oxidation by an additional electron is followed by an irreversible step and a catalytic wave associated with the water oxidation reaction. At pH 1 the reaction with an excess of Ce(IV) results in the generation of an stoichiometric amount of oxygen based on molar amounts of the added Ce(IV). The dominant species during the catalytic cycle is the three‐electron oxidized product, RuIIIRuIVO. The reduction of the concentration of Ce(IV) monitored at 370 nm follow the rate equation, −d[Ce(IV)]/dt=kox[Ce(IV)][RuIIRuIIOH2] with a kox=82±3 M−1s−1 at T=298 K. The RuIIIRuIVO species is not stable and reacts to give RuIIRuIVO.
- 8 December 2021
- Published by Wiley in European Journal of Inorganic Chemistry
- Vol. 2022 (1)
Open AccessA Strongly Coupled Biruthenium Complex as Catalyst for the Water Oxidation Reaction
The catalytic activity towards water oxidation of a strongly coupled bimetallic ruthenium complex, trans‐[Ru(tpy)(bpy)(μ‐CN)Ru(py)4(OH2)]3+ (RuIIRuIIOH2), where tpy=2,2′:6′,2’’‐terpyridine, bpy=2,2′‐bipyridine and py=pyridine are presented. At pH 1 the first two oxidation reactions are centred at the aquo fragment and result in the RuIIRuIIIOH2 and RuIIRuIVO redox states as confirmed by its spectroscopy and DFT calculations. Oxidation by an additional electron is followed by an irreversible step and a catalytic wave associated with the water oxidation reaction. At pH 1 the reaction with an excess of Ce(IV) results in the generation of an stoichiometric amount of oxygen based on molar amounts of the added Ce(IV). The dominant species during the catalytic cycle is the three‐electron oxidized product, RuIIIRuIVO. The reduction of the concentration of Ce(IV) monitored at 370 nm follow the rate equation, −d[Ce(IV)]/dt=kox[Ce(IV)][RuIIRuIIOH2] with a kox=82±3 M−1s−1 at T=298 K. The RuIIIRuIVO species is not stable and reacts to give RuIIRuIVO.
- Open Access
- 10 November 2021
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 25 (6) , 101649
Scope and limitations of a multiplex conventional PCR for the diagnosis of S. stercoralis and hookworms
- 10 November 2021
- Published by Elsevier in The Brazilian Journal of Infectious Diseases
- Vol. 25 (6) , 101649
Open AccessScope and limitations of a multiplex conventional PCR for the diagnosis of S. stercoralis and hookworms
- Open Access
- 18 January 2018
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 12 (1) , e0005945
Assessment of serum pharmacokinetics and urinary excretion of albendazole and its metabolites in human volunteers
Soil Transmitted Helminth (STH) infections negatively impact physical and mental development in human populations. Current WHO guidelines recommend morbidity control of these infections through mass drug administration (MDA) using albendazole (ABZ) or mebendazole. Despite major reductions in STH associated morbidity globally, not all programs have demonstrated the expected impact on prevalence of parasite infections. These therapeutic failures may be related to poor programmatic coverage, suboptimal adherence or the exposure of parasites to sub-therapeutic drug concentrations. As part of the DeWorm3 project, we sought to characterize the serum disposition kinetics and pattern of urinary excretion of ABZ and its main metabolites ABZ sulphoxide (ABZSO) and ABZ sulphone (ABZSO2) in humans, and the assessment of the duration and optimal time point where ABZ and/or its metabolites can be measured in urine as an indirect assessment of an individual’s adherence to treatment. Consecutive venous blood and urine samples were collected from eight (8) human volunteers up to 72 h post-ABZ oral administration. ABZ/metabolites were quantified by HPLC. The ABZSO metabolite was the main analyte recovered both in serum and urine. ABZSO Cmax in serum was 1.20 ± 0.44 μg/mL, reached at 4.75 h post-treatment. In urine, ABZSO Cmax was 3.24 ± 1.51 μg/mL reached at 6.50 h post-ABZ administration. Pharmacokinetic data obtained for ABZ metabolites in serum and urine, including the recovery of the ABZ sulphoxide derivative up to 72 h in both matrixes and the recovery of the amino-ABZ sulphone metabolite in urine samples, are suggesting the possibility of developing a urine based method to assess compliance to ABZ treatment. Such an assay may be useful to optimize ABZ use in human patients. ClinicalTrials.gov NCT03192449. The soil-transmitted-helminths (STH) infections are produced by four species of parasites: Ascaris lumbricoides, Trichuris trichiura, and hookworm (Necator americanus and Ancylostoma duodenale). These parasites are transmitted by eggs present in human faeces, which contaminate the environment in areas where sanitation is poor. These diseases negatively impact health and development. Current STH control is based on mass drug administration (MDA) programs, mainly through the use of albendazole (ABZ) and mebendazole. However, although MDA programs have been shown to reduce the prevalence of STH infection and to control morbidity in school-age children, rapid reinfection is common among treated children and many programs fail to reach coverage targets. Optimizing methods to assess treatment coverage may allow programs to more effectively deliver MDA to populations requiring treatment. We conducted a controlled trial to evaluate the serum pharmacokinetic behaviour and urinary excretion of ABZ and its metabolites in human volunteers. The study focused also on to evaluate, by mean of non-invasively measures, ABZ treatment coverage and adherence. The measurement of ABZSO concentrations both in serum and urine may be useful methods to monitor adherence to ABZ treatment and serve as a more objective measurement of program coverage.
- 18 January 2018
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 12 (1) , e0005945
Open AccessAssessment of serum pharmacokinetics and urinary excretion of albendazole and its metabolites in human volunteers
Soil Transmitted Helminth (STH) infections negatively impact physical and mental development in human populations. Current WHO guidelines recommend morbidity control of these infections through mass drug administration (MDA) using albendazole (ABZ) or mebendazole. Despite major reductions in STH associated morbidity globally, not all programs have demonstrated the expected impact on prevalence of parasite infections. These therapeutic failures may be related to poor programmatic coverage, suboptimal adherence or the exposure of parasites to sub-therapeutic drug concentrations. As part of the DeWorm3 project, we sought to characterize the serum disposition kinetics and pattern of urinary excretion of ABZ and its main metabolites ABZ sulphoxide (ABZSO) and ABZ sulphone (ABZSO2) in humans, and the assessment of the duration and optimal time point where ABZ and/or its metabolites can be measured in urine as an indirect assessment of an individual’s adherence to treatment. Consecutive venous blood and urine samples were collected from eight (8) human volunteers up to 72 h post-ABZ oral administration. ABZ/metabolites were quantified by HPLC. The ABZSO metabolite was the main analyte recovered both in serum and urine. ABZSO Cmax in serum was 1.20 ± 0.44 μg/mL, reached at 4.75 h post-treatment. In urine, ABZSO Cmax was 3.24 ± 1.51 μg/mL reached at 6.50 h post-ABZ administration. Pharmacokinetic data obtained for ABZ metabolites in serum and urine, including the recovery of the ABZ sulphoxide derivative up to 72 h in both matrixes and the recovery of the amino-ABZ sulphone metabolite in urine samples, are suggesting the possibility of developing a urine based method to assess compliance to ABZ treatment. Such an assay may be useful to optimize ABZ use in human patients. ClinicalTrials.gov NCT03192449. The soil-transmitted-helminths (STH) infections are produced by four species of parasites: Ascaris lumbricoides, Trichuris trichiura, and hookworm (Necator americanus and Ancylostoma duodenale). These parasites are transmitted by eggs present in human faeces, which contaminate the environment in areas where sanitation is poor. These diseases negatively impact health and development. Current STH control is based on mass drug administration (MDA) programs, mainly through the use of albendazole (ABZ) and mebendazole. However, although MDA programs have been shown to reduce the prevalence of STH infection and to control morbidity in school-age children, rapid reinfection is common among treated children and many programs fail to reach coverage targets. Optimizing methods to assess treatment coverage may allow programs to more effectively deliver MDA to populations requiring treatment. We conducted a controlled trial to evaluate the serum pharmacokinetic behaviour and urinary excretion of ABZ and its metabolites in human volunteers. The study focused also on to evaluate, by mean of non-invasively measures, ABZ treatment coverage and adherence. The measurement of ABZSO concentrations both in serum and urine may be useful methods to monitor adherence to ABZ treatment and serve as a more objective measurement of program coverage.
- Open Access
- 5 October 2017
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 11 (10) , e0005980
Reappraisal of Leishmanin Skin Test (LST) in the management of American Cutaneous Leishmaniasis: A retrospective analysis from a reference center in Argentina
Leishmania (Viannia) braziliensis is the species most frequently implicated with cutaneous and mucosal leishmaniasis in the Americas; its diagnosis is based on the identification of amastigotes in lesions, which is limited by low parasite burden. Leishmanin Skin Test (LST) is a support tool for diagnosis, based on delayed type hypersensitivity responses to Leishmania antigens injected intradermally, used in endemic areas as a complement to diagnosis. A retrospective analysis of individuals evaluated for their first episode of tegumentary leishmaniasis at a reference center in Argentina during the period 2006–2015 was performed, with the goal of assessing its usefulness as a support tool in the diagnosis of leishmaniasis. Demographic, clinical and diagnostic work-up were analyzed in individuals with clinically compatible lesions, lesion`s smear and LST. A total of 733 cases that met the case definition were included in the analysis; 678 (93%) localized cutaneous cases, 50 (7%) with mucosal involvement and 5 (Leishmania antigens injected intradermally into the patient´s forearm and measured as the induration size after 48 hours. This analysis of 733 cases, which is the largest series of cases evaluating the role of LST in ACL highlights and establishes the usefulness of this complementary diagnostic tool with a strong correlation with lesion smear and a demonstration that false positive responses due to previous exposure to the parasite are not of concern. The results support the use of LST in endemic areas to assist in guiding clinical decisions regarding treatment initiation.
- 5 October 2017
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 11 (10) , e0005980
Open AccessReappraisal of Leishmanin Skin Test (LST) in the management of American Cutaneous Leishmaniasis: A retrospective analysis from a reference center in Argentina
Leishmania (Viannia) braziliensis is the species most frequently implicated with cutaneous and mucosal leishmaniasis in the Americas; its diagnosis is based on the identification of amastigotes in lesions, which is limited by low parasite burden. Leishmanin Skin Test (LST) is a support tool for diagnosis, based on delayed type hypersensitivity responses to Leishmania antigens injected intradermally, used in endemic areas as a complement to diagnosis. A retrospective analysis of individuals evaluated for their first episode of tegumentary leishmaniasis at a reference center in Argentina during the period 2006–2015 was performed, with the goal of assessing its usefulness as a support tool in the diagnosis of leishmaniasis. Demographic, clinical and diagnostic work-up were analyzed in individuals with clinically compatible lesions, lesion`s smear and LST. A total of 733 cases that met the case definition were included in the analysis; 678 (93%) localized cutaneous cases, 50 (7%) with mucosal involvement and 5 (Leishmania antigens injected intradermally into the patient´s forearm and measured as the induration size after 48 hours. This analysis of 733 cases, which is the largest series of cases evaluating the role of LST in ACL highlights and establishes the usefulness of this complementary diagnostic tool with a strong correlation with lesion smear and a demonstration that false positive responses due to previous exposure to the parasite are not of concern. The results support the use of LST in endemic areas to assist in guiding clinical decisions regarding treatment initiation.